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Uterine leiomyosarcoma (LMS) develops more often in the muscle tissue layer of the uterine body than in the uterine cervix.
The development of gynecologic tumors is often correlated with female hormone secretion; however, the development of uterine
LMS is not substantially correlated with hormonal conditions, and the risk factors are not yet known. Importantly, a diagnostic-
biomarker which distinguishes malignant LMS from benign tumor leiomyoma (LMA) is yet to be established. Accordingly, it is
necessary to analyze risk factors associated with uterine LMS, in order to establish a treatment method. LMP2-deﬁcient mice
spontaneously develop uterine LMS, with a disease prevalence of ∼40% by 14 months of age. We found LMP2 expression to be
absent in human LMS, but present in human LMA. Therefore, defective LMP2 expression may be one of the risk factors for LMS.
LMP2 is a potential diagnostic-biomarker for uterine LMS, and may be targeted-molecule for a new therapeutic approach.
1.Introduction
The uterus is the female reproductive organ, located at the
center of the pelvis between the left and right ovaries. The
uterus, the organ in which the embryo grows, is composed
of three layers, the uterine endometrium which serves as
a bed for the embryo; the myometrium of the wall which
protects the embryo; and a serous membrane enveloping the
uterus. The myometrium is composed of smooth muscle.
In general, the term uterine tumor refers to an epithelial
malignant tumor of the uterus, which is roughly classiﬁed
as a tumor of the uterine cervix or the uterine body.
Because of the prevalence of screening, uterine cervix cancer
is decreasing in incidence, and usually detected at a very
early stage, including stage 0. In contrast, cancer of the
uterine body is increasing in incidence, and rarely detected
at the initial stages. While most tumors of the uterine body
are adenocarcinomas (derived from the subintimal gland),
tumors of the uterine cervix are classiﬁed into squamous
cancer and adenocarcinoma. The myometrium is composed
of smooth muscle. Smooth muscle tumors (SMTs) which
develop in the myometrium have been traditionally divided
into benign LMA and malignant LMS based on cytological
atypia, mitotic activity and other criteria. Uterine LMS, one
of the most common neoplasms of the female genital tract,
is relatively rare, having an estimated annual incidence of2 Sarcoma
0.64per100,000women[1].UterineLMSaccountsfor2%to
5% of tumors of the uterine body and develops more often
in the muscle layer of the uterine body than in the uterine
cervix [2, 3]. Distinguishing uterine LMA from uterine LMS
is very diﬃcult, and a diagnosis generally requires surgery
and cytoscopy.
The cause of tumors of the uterine cervix has been
found to be the human papilloma virus, in combination
with other factors. An infection is established by sexual
activity. In contrast, a main factor in the development of
tumors in the uterine body is the hormonal environment.
Patients with uterine body tumors oftenare unmarried, have
never been pregnant, and are taking a hormonal agent. High
estrogen levels are considered to signiﬁcantly inﬂuence the
development of such tumors. The mechanisms by which
uterine LMA and LMS develop are not yet known, though
tumorcellsthathavedevelopedinthemyometrium forsome
reason gradually become larger due to the inﬂuence of the
female hormone, estrogen, and generate tumors. However,
no correlation between the developmentof uterine LMS and
hormonal conditions, and no obvious risk factors have been
found. The prognosis of uterine LMS is not good, and the
ﬁve-year survival rate is approximately 35%, although the
ﬁve-year survival rate depends on disease stage [2, 3]. It is
worthnotingthat,whenadjustedforstageandmitoticcount,
LMShasasigniﬁcantlyworseprognosisthancarcinosarcoma
[4]. As uterine LMS is resistant to chemotherapy and
radiotherapy, and thus surgical intervention is virtually the
only means of treatment [5–7], developing an eﬃcient
adjuvant therapy is expected to improve the prognosis of the
disease. Although cases accompanied by hypocalcaemia or
eosinophiliahavebeenreported, neitherclinicalabnormality
is an initial risk factor for uterine LMS. The identiﬁcation
of a risk factor associated with the development of uterine
LMS would signiﬁcantly contribute to the development of
preventive and therapeutic treatments.
2.Biological Rolesofthe Immunoproteasome
When tissue or an organ is transplanted, the graft is often
lost due to an acute rejection caused by the host immune
system. This is because the cell surface antigens presented by
themajorhistocompatibilitycomplex(MHC)areintrinsic to
an individual and so diﬀer between the donor and recipient.
The immunological selfmarkers on cell surfaces are the most
important immune system for higher vertebrates such as
mammals, protecting the self from invaders. Cytoplasmic
proteins are mostly degraded by a protease complex, which
has many substrates consisting of twenty-eight 20 to 30-
kDa subunits, referred to as the immunoproteasome [8].
The proteasomal degradation pathway is essential for many
cellular processes, including the cell cycle, the regulation of
gene expression, and others. The proteasomal degradation
pathway is also essential for the production of peptide
antigens which are presented by MHC class I. That is, the
immunoproteasome plays a key role in the presentation of
immunological self markers on the cell surface by MHC
(Figure 1)[ 8]. Interferon-γ (IFN-)γ) is a critical inducer of
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Figure 1: Mediation of the proteasomal degradation pathway to
antigen presentation by MHC class I. The immunoproteasomal
degradation pathway is essential for antigen presentation by MHC
class I. Defecive LMP2 expression results in tissue- and substrate-
dependent abnormalitiesof immunoproteasomalfunctions. There-
fore an impaired proteasome may promote the initial development
of disease including tumorigenesis.
the immunoproteasome’s expression in immune systems [9].
Recent ﬁndings have veriﬁed that IFN-γ prevents primary
tumor development, thereby showing a tumor suppressor
role in the immune response [10, 11]. IFN-γ upregulates the
expression oflargenumbers ofresponsive genes,also,expres-
sion of the immunoproteasome’s subunits, that is, low-
molecular mass polypeptide (LMP) 2, LMP7, and LMP10,
is markedly induced by IFN-γ signaling [9, 12]. The IFN-γ-
inducibleproteasomalfunction playsakeyroleinMHCclass
I-mediated tumor rejection [11, 13]. Further, a molecular
approach to studying the correlation of IFN-γ with tumor
cell growth has drawn attention. A deﬁciency of IFN-γ
apparently does not hamper the generation of CTL [10,
11]. Recent reports have demonstrated the multifunctional
deﬁciencies of components of the MHC class I antigen-
presentation pathway including LMP2 and TAP-1 in tumor
cells [11, 13]. A possible role for the IFN-γ-responsive gene
TAP-1 in tumor recognition was reported [11]. Here we
identify LMP2, a single IFN-γ-responsive gene product, as
obligatory for tumor surveillance [12] and demonstrate a
tissue-speciﬁc roleforLMP2inprotectionfromspontaneous
neoplasms of the uterus.
3.Development ofMalignant Uterine Tumorin
LMP2-Deﬁcient Mice
Malignant tumors originate from a single cancerous cell and
develop as a result of unlimited cell proliferation. Malignant
tumor cells have properties that are biologically diﬀerent
from those of normal cells. Thus, the host immune system
should be able to distinguish malignant tumor cells from
corresponding normal cells. That is, malignant tumor cells
present intrinsic antigens (i.e., tumor-cell-speciﬁc antigens
that can be the targets of immune responses are referred
to as tumor-antigens (TA)) on the cell surface with the
aid of MHC. In many cases, however, almost no reaction
by the immune system is observed. Also, the incidence of
major tumors isnot very diﬀerent betweenimmunodeﬁcientSarcoma 3
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Figure 2: Histological ﬁndings of uterine leiomyosarcomain LMP2-deﬁcient mice. Histological ﬁndings of uterine LMS in LMP2-deﬁcient
mice ((a) to (c)). Among the histological ﬁndings of uterine LMS in LMP2-deﬁcient mice, a cytoskeleton, which is characteristic of uterine
LMS, is observed. ((b) and (c) magniﬁcation x400) Panel (e), in LMP2-deﬁcient females, uterine LMS is observed at 6 months of age. The
incidence at age 14 months is as high as 40% (e). The curve indicating the incidence of mouse uterine LMS is very similar to that indicating
the incidence of human uterine LMS, which is observed after menopause. In mice with tumors of the uterus, signiﬁcant weight loss is
observed. Thus, a tumor that develops in the uterus is diagnosed as malignant, that is, uterine LMS.
(i.e., lymphocyte-deﬁcient) mice and control mice having
normal immune systems. Speciﬁcally, tumor cells can avoid
the immune monitoring system via several means [14,
15]. Naturally occurring tumor cells seem to have lost the
expression of peptide antigens, TA, or cell adhesion factors
intrinsic to tumors. Tumor cells may avoid the host immune
reaction due to the absence of MHC expression, although
no such mechanism has yet been elucidated. However, it is
important to demonstrate how tumor cells evade immune-
responses, in order to prevent the development of tumors.
The genes encoding LMP2, LMP7, TAP1, and TAP2,
are located in region H-2 which encodes the murine MHC
molecule. LMP2-deﬁcient mice show tissue- and substrate-
dependent abnormalities in the biological functions of
the immunoproteasome, and impaired functioning of the
immunoproteasome in the spleen or hepatic cells [16].
Further, LMP2-deﬁcient mice do not show normal immune
responses to virus-infected cells, and such immunopathy
is known to result from a failure in the presentation of
peptide antigens on the cell surface by MHC [16]. We
found that uterine LMS occurred in female LMP2-deﬁcient
mice at age 6 months or older, and the incidence at 14
months of age was about 40% [17]( F i g u r e2). The curve
indicating the incidence in mice is very similar to that
indicating the incidence of human uterine LMS, which
occursaftermenopause.HistologicalexaminationsofLMP2-
lacking uterine tumors revealed characteristic abnormalities
of LMS [17]. The tumors lacked lymphoid inﬁltrates, a sign
of immune recognition, and consisted of uniform elongated
smooth musclecells arranged into bundles. The nuclei of the
tumor cells varied in size and shape; furthermore, mitosis
was frequent, in contrast, the uterine smooth muscle cells4 Sarcoma
of C57BL/6 mice were normal in appearance [17]. Whereas
relatively few Ki-67-positive cells, the proliferating cells of
solid tumors, were observed in the basal cell layer of the
normal uterine smooth muscle, most of the basal cells
vividly expressed Ki-67 in LMP2-deﬁcient mice [17]. This
immunohistochemical (IHC) staining indicates abnormal
proliferation of the LMP2-lacking cells in the basal layer [17]
(Figure 2). LMP2-deﬁcient mice that have developed uterine
LMS undergo considerable weight loss, and then die by 14
months of age [17]. The LMP2-deﬁcient mice also exhibit
skeletal muscle metastasis from uterine LMS. Therefore it is
likeLMP2-deﬁcientmicewithuterineLMShavediedofmass
eﬀect and metastasis. In general, it is not easy to distinguish
uterine LMA from LMS. However, in mice, because of such
characteristic pathological ﬁndings, signiﬁcant weight loss,
and exhibition of skeletal muscle metastasis, a tumor that
develops in the uterus of an LMP2-deﬁcient mouse can be
considered malignant, that is, a uterine LMS.
If the TP53 gene is damaged, tumor suppression is
severely reduced. People who inherit only one functional
copy of the TP53 gene will most likely develop tumors
in early adulthood, a disease known as Li-Fraumeni syn-
drome. More than 50 percent of human tumors contain a
mutation or deletion of the TP53 gene [18]. To increase
tumor incidence and better assess the role of systemic
expression of TP53 in responses to initiation of uterine LMS
tumorigenesis, LMP2-deﬁcient mice were bred with TP53-
deﬁcient mice to create Lmp2−/−Tp53−/− double knock-
out mice. Uterine LMS incidence and death rates were sim-
ilar in Lmp2−/−Tp53−/− mice and closely matched control
Lmp2−/−Tp53+/+ mice. The correlation of defective TP53
function with uterine LMS tumorigenesis is not clearly un-
derstood.
4.InactivationoftheIRF-1TumorSuppressor
Gene inLMP2-DeﬁcientMice
Uterine LMS was demonstrated to spontaneously develop in
6-month-old LMP2-deﬁcient mice at high frequency. The
expression of LMP2 was signiﬁcantly induced by IFN-γ as
was the expression of other subunits [9, 12]. Accordingly,
the expression of cell-cycle regulators that are regulated by
the IFN-γ signal cascade or immunoproteasome activity was
examined. Signal transducer and activator of transcription
(STAT) 1, having been activated by IFN-γ,s i g n i ﬁ c a n t l y
induced expression of tumor suppressors such as interferon
regulatory factor 1 (IRF1) [19, 20]. IRF1 as a transcriptional
regulator signiﬁcantly regulates LMP2 expression [19, 20].
It was examined whether the IFN-γ signal cascade induces
the expression of each subunit of the immunoproteasome
and IFR1 and IRF2 in LMP2-deﬁcient mice and the parental
strain, C57BL/6. No signiﬁcant diﬀerence was observed in
the expression of STAT1 and the subunits LMP7, LMP10,
CP9, and IRF2. Also, IFN-γ-induced phosphorylation of
STAT1 would not be inﬂuenced by a lack of LMP2. How-
ever, the expression of IRF1 was signiﬁcantly reduced in
splenocytes derived from mice lacking LMP2 in comparison
with wild-type mice. IRF1 expression in LMP2-deﬁcient
LMP2−/− IRF1, p21WAF CDK2/cyclin E
Calponin h1
decrease
Activation
Others
Myometrium LMS
Figure 3: Model of the mechanism for development of uterine
leiomyosarcoma. In LMP2-deﬁcient cells, levels of the antionco-
genic factor IRF-1, p21WAF are signiﬁcantly reduced. Reduced
expression of the calponin h1 transcript, which contributes to cell
proliferation and tumorigenesis in uterine smooth muscle cells,
is detected in uterine LMS tissues. Cell cycle regulatory factors,
CDK2/Cyclin E, are markedly activated. The inactivation of such
antioncogenic factors is considered to transform LMP2-deﬁcient
cells into malignanttumor cells.
splenocytes was not induced by the IFN-γ signal cascade.
In addition, wild type-mouse embryonic ﬁbroblasts (MEFs)
that had been treated with the proteasome inhibitor MG-
132 exhibited a loss of IFN-γ-inducibility, reproducing a
phenotype of the LMP2-deﬁcient mouse. Accordingly, the
transcription of Irf1 mRNA depends on the immunoprotea-
some’s function and is considered to involve the formation
ofaSTAT1homodimer.Recentreportssuggestthatproteaso-
malfunctioncontributestomRNAtranscriptionalactivation
[21, 22].
Primary cultured tumor cells (LMP2-UC) were estab-
lished from the uterine LMS of LMP2-deﬁcient mice,
and then IRF1-overexpressing tumor cells (LMP2-UC-
IRF1) were further established by genetic engineering. The
LMP2-UC-IRF1 cells were intracutaneously transplanted
into immunodeﬁcient mice (BALB/c nu/nu), and signiﬁcant
inhibiting eﬀects of IRF1 on tumor cell proliferation were
observed [20, 23]. Thus, a lowered level of IRF1 resulting
from a deﬁciency in LMP2 seemed to be a risk factor
for uterine LMS in mice. The eﬀects of IRF1 on tumor
cell proliferation are achieved through the expression of
p21WAF cell-cycle inhibitors (inhibiting transition from the
G1 to S stage) [24]. Whether or not p21WAF expression
or activation is aﬀected in LMP2-deﬁcient mice should be
examined further. The tumor suppressor, retinoblastoma
(Rb) is phosphorylated by a complex of Cyclin E/Cyclin
dependent kinase 2 (CDK2) and then inactivated [25]. Also,
the activity of CDK2 is negatively regulated via degradation
of Cyclin E by the 26S proteasome [26, 27]. A signiﬁcant
level of phosphorylated-Rb is observed in MEFs-lacking
LMP2, and the activity of CDK2 for phosphorylation is
determined to be stronger than that in normal MEFs.
However research overall, including experiments with gene-
deﬁcient mouse models and clinical studies, suggests that
defective Rb expression does not take part in the onset
of uterine LMS [28–30]. In the case of uterine LMS in
LMP2-deﬁcient mice, defective IRF1 is considered to be
involved in cellular transformation and cell proliferation
(Figure 3).Sarcoma 5
5.Perspectives
Uterine LMS mainly develops in the uterine smooth muscle
orendometrialstroma, andmenstrualanomalies, suchashy-
permenorrhea and prolonged menstruation, and symptoms
such as abnormal hemorrhage, hypogastric pain, lumbar
pain, and abdominal strains, are observed [4]. In the case
of gynecological cancers, such as breast cancer, a female
hormonal imbalance is often a risk factor for developing
tumors.AsinthecaseofuterineLMA,however,acorrelation
between the development of uterine LMS, the female hor-
mone, and hormone receptors has yet to be elucidated [31,
32]. A recent report showed the expression of Lmp2 mRNA
and protein in luminal and glandular epitheliua, placenta
villi, trophoblastic shells, and arterial endothelial cells [33].
These results implicate LMP2 in the invasion of placen-
tal villi, degradation of the extracellular matrix, immune
tolerance, glandular secretion, and angiogenesis [33]. The
present study should help to elucidate the regulatory role
of the ubiquitin-proteasome pathway in the implantation
of embryos. Unfortunately, it is unclear whether defective
LMP2 expression is involved in the onset of uterine LMS.
Uterine LMS often seems to develop in individuals exposed
to radiation in the pelvis. Risk factors for its development,
however, have not been identiﬁed because of the absence
of a suitable animal model. The LMP2-deﬁcient mouse was
the ﬁrst animal model of spontaneous uterine LMS to be
established [17]. Defective LMP2 expression may be one of
the causes of uterine LMS [20]. To demonstrate whether
LMP2 is a potential biomarker for distinguishing LMS from
LMA,weareinvestigatingthereliabilityandcharacteristicsof
LMP2 as a diagnostic indicator with several clinical research
facilities. The clinical research is yet to be concluded, and
large-scale clinical studies need to be performed. In some
cases, uterine LMA may become malignant and develop
into uterine LMS. Accordingly, the correlation between
the inactivation of LMP2 and the development of uterine
LMA needs to be examined. Although LMS usually lacks
lymphoid inﬁltrates recognizable on routine histological
staining, further histological examination revealed a few
inﬁltrating CD56+ natural killer cells in human uterine LMS
tissues. Deﬁnitive histological studies must be performed,
including the gene-expression proﬁling of several known
pro-oncogenicfactors aswell as factors such asbrain-speciﬁc
polypeptide PEP-19 and a transmembrane tyrosine kinase
receptor, C-kit [34–36]. The reduced expression of calponin
h1 transcripts was reported to be associated with uterine
LMS,andcalpononh1 mightfunction asa tumorsuppressor
in uterine LMS [37, 38]. A recent study showed that re-
expression of human calponin h1 suppressed cell prolifer-
ation and tumorigenesis in uterine LMS cells [38]. Since
no spontaneous development of uterine LMS is observed
in IRF1-, calponin h1-deﬁcient mice or heterozygous Rb
mice, the lack of LMP2 is largely associated with the
expression of other known or unknown cell-cycle regulatory
factors. Further research is required to demonstrate the
correlative functions of LMP2 and other antioncogenic
factors with calponin h1 in the tumorigenesis of uterine
LMS. Clariﬁcation of the correlation between these factors
and the development of uterine LMS and the identiﬁcation
of speciﬁc risk factors may lead to the development of
new treatments for the disease. Uterine LMS is refractory
to chemotherapy and has a poor prognosis. The molecular
biologicalandcytologicalinformation obtainedfromLMP2-
deﬁcientmicewillcontributeremarkablytothedevelopment
ofpreventivemethods,apotentialdiagnostic-biomarker,and
new therapeutic approaches against uterine LMS.
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